Immuron IMRN 深 滬
等待開盤 08-10 09:30:00 美东时间
1.031
-0.069
-6.27%
華盛通- 最 高1.0651
- 今 開1.0651
- 成交量 9252股
- 最 低 1.02
- 昨 收 1.10
- 總市值 832.14万
- 52周最高 2.39
- 市盈率 靜 --
- 換手率 0.11%
- 52周最低 0.6765
- 委 比 92.13%
- 總股本 807.12万
- 歷史最高 28.99
- 量 比 0.54
- 振 幅 4.10%
- 歷史最低 0.6765
- 每 手 1
- 風險率 0.47%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Immuron Showcases Oral Antibody Platform in July 20 Investor Presentation
The latest announcement is out from Immuron ( ($IMRN) ). Immuron Limited has hi...
07-20 20:27
Immuron CEO, Steven Lydeamore presentation at Kalkine Media Webinar
Immuron Limited (ASX: IMC; NASDAQ: IMRN) announced that CEO Steven Lydeamore will present virtually at the Kalkine Media Webinar on July 20, 2026. The presentation slides are available on the company’s website. Immuron focuses on developing orally delivered antibodies for infectious diseases. Its products include Travelan® for travelers’ diarrhea, IMM-529 for C. diff infection, and ProIBS® for IBS. The company’s platform technology uses hyperimmu...
07-20 10:00
Immuron Sees Prelim FY2026 Sales $5.462M
Immuron (NASDAQ:IMRN) sees Prelim FY2026 sales of $5.462 million.
07-16 18:25
Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year
Immunon Limited reported FY26 sales growth for Travelan®, with global sales up 6% to AUD$7.7 million. Australia saw a 10% increase to AUD$5.8 million, driven by digital marketing and new store expansions. U.S. sales rose 7% (AUD) and 13% (USD), supported by improved Amazon presence and social media efforts. Canada experienced strong Q4 growth, up 376% on pcp, following consumer promotions and brand awareness campaigns. Travelan® is an over-the-co...
07-16 10:00
Immuron Hires Pullan To Find Partner For Gut Infection Drug, Seeks Strategic Partner For FDA-Cleared IMM-529 Trial
Immuron Limited ((ASX: IMC, NASDAQ:IMRN) is pleased to announce that it has engaged Pullan Consulting to provide business development services to assist in securing a strategic partnership for IMM-529. Pullan Consulting is a highly regarded life sciences advisory firm with a strong track record of e...
07-06 18:05
Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy
Immuron has engaged Pullan Consulting to secure a strategic partnership for IMM-529, a drug targeting Clostridioides difficile infection (CDI). IMM-529 has FDA approval for its IND application and offers a multi-target approach with polyclonal antibodies, providing advantages over monoclonal antibodies and antibiotics. The drug is in Phase 2 clinical trials, with plans for a randomized, double-blind study assessing safety, tolerability, and effic...
07-06 10:00
Immuron Says No Undisclosed News Behind Share Price Spike
Immuron Limited ( ($AU:IMC) ) has shared an announcement. Immuron Limited has r...
05-28 11:08
Immuron shares are trading higher after the company reported a year-over-year increase in its Q3 sales results.
Immuron shares are trading higher after the company reported a year-over-year i...
04-17 23:46
Immuron Q3 sales rise 16% to A$1.5M
Immuron reported third-quarter global sales of A$1.5 million, up 16% from the prior comparative period, while year-to-date sales through March 2026 rose 7% to A$5.7 million. In the US, Q3 sales came i...
04-17 19:34
Immuron Double Digit 3Q Sales Growth
Immuron Limited reported Q3 sales growth for Travelan® with a 16% increase globally and 15% in Australia, driven by digital marketing and store expansion. U.S. sales rose 1% despite currency challenges, while Canada saw a 82% quarterly increase but a 65% YTD decline. The company highlights Travelan® as an immune supplement targeting gastrointestinal pathogens and emphasizes its platform technology for developing orally active antibodies.
04-17 10:00
